A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Public ClinicalTrials.gov record NCT04970901. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
Study identification
- NCT ID
- NCT04970901
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 154 participants
Conditions and interventions
Conditions
Interventions
- Loncastuximab Tesirine Drug
- Polatuzumab Vedotin Drug
- Glofitamab Drug
- Mosunetuzumab Drug
- Obinutuzumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 17, 2022 (Actual)
- Primary completion
- Mar 31, 2027 (Estimated)
- Completion
- Apr 30, 2028 (Estimated)
- Last update posted
- Jul 17, 2026
2022 – 2028
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco - Fresno Center for Medical Education and Research | Clovis | California | 93611 | — |
| Scripps Health - Prebys Cancer Center | San Diego | California | 92103 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| Memorial Cancer Institute - Memorial Hospital West | Pembroke Pines | Florida | 33028 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| The Blood and Marrow Transplant Group of Georgia | Atlanta | Georgia | 30342 | — |
| Mission Cancer + Blood - Mission Cancer Foundation | Des Moines | Iowa | 50309 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Columbia University Irving Medical Center | New York | New York | 10027 | — |
| Cleveland Clinic Main Campus | Cleveland | Ohio | 44195 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Penn Medicine - Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104 | — |
| Allegheny Health Network - West Penn Hospital | Pittsburgh | Pennsylvania | 15224 | — |
| Brown University Health - Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR) | Nashville | Tennessee | 37203 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Emily Couric Clinical Cancer Center | Charlottesville | Virginia | 22903 | — |
| NEXT Virginia (Virginia Cancer Specialists) | Fairfax | Virginia | 22031 | — |
| Froedtert & Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04970901, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 17, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04970901 live on ClinicalTrials.gov.